Public Health Key Documents: June 2021

**NIHR**

[**High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation**](https://www.journalslibrary.nihr.ac.uk/hta/hta25330/#/abstract)

High-sensitivity troponin assays may be more cost-effective than standard troponin testing, and strategies involving multiple tests are likely to be more effective than a single test.

Systematic search: Yes

June 2021

**The King’s Fund**

[**My role in tackling health inequalities: a framework for allied health professionals**](https://www.kingsfund.org.uk/sites/default/files/2021-06/AHP%20Health%20Inequalities%20Framework.pdf)

Report prepared for Public Health England, NHS England and NHS Improvement. The King’s Fund worked with AHPs from across the UK to develop a framework to support any AHP to think through and understand their contribution to tackling health inequalities, whatever their role. The framework details how AHPs can raise awareness, take action and optimise advocacy through six lenses: self; patients; clinical teams, pathway and service groups; communities and networks; systems; and nurturing the future. Includes examples.

Systematic search: No

June 2021

**Scottish Medicines Consortium (SMC Advice)**

[**acalabrutinib (Calquence®)**](https://www.scottishmedicines.org.uk/medicines-advice/acalabrutinib-calquence-full-smc2347/)

Accepted for restricted use as monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) without a del(17p) or TP53 mutation and who are ineligible for fludarabine, cyclophosphamide and rituximab (FCR) therapy.

Systematic search: No

June 2021

[**baricitinib (Olumiant®)**](https://www.scottishmedicines.org.uk/medicines-advice/baricitinib-olumiant-full-smc2337/)

Accepted for restricted use for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.

Systematic search: No

June 2021

[**mogamulizumab (Poteligeo®)**](https://www.scottishmedicines.org.uk/medicines-advice/mogamulizumab-poteligeo-full-smc2336/)

Accepted for restricted use for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy who are clinically ineligible for, or refractory to treatment with, brentuximab vedotin.

Systematic search: No

June 2021

[**nintedanib (Ofev®)**](https://www.scottishmedicines.org.uk/medicines-advice/nintedanib-ofev-full-smc2331/)

Accepted for use in adults for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype other than idiopathic pulmonary fibrosis (IPF).

Systematic search: No

June 2021

[**trifluridine/tipiracil (Lonsurf®)**](https://www.scottishmedicines.org.uk/medicines-advice/trifluridinetipiracil-lonsurf-full-smc2329/)

Accepted for restricted use as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Systematic search: No

June 2021

[**vigabatrin (Kigabeq®)**](https://www.scottishmedicines.org.uk/medicines-advice/vigabatrin-kigabeq-abb-smc2352/)

Accepted for restricted use in infants and children from 1 month to less than 7 years of age for:

treatment in monotherapy of infantile spasms (West's syndrome); also as treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.

Systematic search: No

June 2021

**Scottish Government**

[**Equally safe - challenging men's demand for prostitution: consultation analysis**](https://www.gov.scot/publications/equally-safe-challenging-mens-demand-prostitution-analysis-public-consultation-findings/)

[**Equally safe - challenging men's demand for prostitution: Scottish Government response**](https://www.gov.scot/publications/equally-safe-challenging-mens-demand-prostitution-working-reduce-harms-associated-prostitution-helping-women-exit-scottish-government-response/)

Analysis of responses to a public consultation seeking views on how best to challenge men’s demand for prostitution in Scotland, reducing the harms associated with prostitution and supporting women involved to exit – and the Scottish Government’s response to the consultation.

Systematic search: No

June 2021

**['Covid Conversations': experiences of the pandemic in Scotland](https://www.gov.scot/publications/covid-conversations-experiences-pandemic-scotland/)**

Findings from qualitative research carried out between December 2020 and February 2021 (via online focus groups).

Systematic search: No

June 2021

**Please note:** Covid-19 data and statistics, advice and guidance are available from <https://www.gov.scot/coronavirus-covid-19/> with further publications available at <https://www.gov.scot/publications/?topics=Coronavirus+in+Scotland>

**SIGN**

Nil

**Public Health Scotland**

[**Evaluating the impact of Minimum Unit Pricing (MUP) on the price distribution of off-trade alcohol in Scotland**](https://www.publichealthscotland.scot/publications/evaluating-the-impact-of-minimum-unit-pricing-mup-on-the-price-distribution-of-off-trade-alcohol-in-scotland/)

After the introduction of MUP, there was an increase in the proportion of alcohol sold above the 50 pence per unit price floor. In the 12 months following implementation 65.3% of off-trade alcohol sold was categorised between 50 and 64.9 pence per unit. This was approximately double that seen in both England & Wales Scotland in the year pre-mup. The changes that drove this increase were seen in drink categories sold at the lower end of the price distribution prior to MUP, (beer, spirits, cider and perry). MUP has had limited effect on the price distribution above 65p per unit.

Systematic search: No

June 2021

[**MESAS (Monitoring and Evaluating Scotland's Alcohol Strategy) monitoring report 2021**](https://www.publichealthscotland.scot/publications/mesas-monitoring-report-2021/)

The latest data on key alcohol indicators in Scotland.

Systematic search: No

June 2021

[**Healthy housing for Scotland**](https://www.publichealthscotland.scot/publications/healthy-housing-for-scotland/)

Briefing paper setting out the link between housing and public health. Intended to support the Scottish Government’s ‘Housing to 2040’ vision.

Systematic search: No

June 2021

**NICE – Guidelines**

[**NG197 Shared decision making**](https://www.nice.org.uk/guidance/ng197)

Covers how to make shared decision making part of everyday care in all healthcare settings and promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. Includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.

Systematic search: Yes

June 2021

**NICE - Technology Appraisal Guidance**

[**TA708 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis**](https://www.nice.org.uk/guidance/ta708)

Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.

Systematic search: Yes

June 2021

[**TA709 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency**](https://www.nice.org.uk/guidance/ta709)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

Systematic search: Yes

June 2021

[**TA710 Ravulizumab for treating atypical haemolytic uraemic syndrome**](https://www.nice.org.uk/guidance/ta710)

Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

Systematic search: Yes

June 2021

[**TA707 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer**](https://www.nice.org.uk/guidance/ta707)Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

Systematic search: Yes

June 2021

[**TA706 Ozanimod for treating relapsing–remitting multiple sclerosis**](https://www.nice.org.uk/guidance/ta706)

Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

Systematic search: Yes

June 2021

[**TA705 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer**](https://www.nice.org.uk/guidance/ta705)

Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.

Systematic search: Yes

June 2021

[**TA704 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies**](https://www.nice.org.uk/guidance/ta704)

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies**.**

Systematic search: Yes

June 2021

**EPPI Centre**

Nil

**AHRQ (Agency for Healthcare Research and Quality – USA)**

[**Radiation Therapy for Brain Metastases**](https://effectivehealthcare.ahrq.gov/products/radiation-therapy-brain-metastases/research)

Despite the substantial research literature on radiation therapy, comparative effectiveness information is limited. There is a need for more data on patient-relevant outcomes such as quality of life, functional status, and cognitive effects.

Systematic search: Yes

June 2021

[**Prehospital Airway Management**](https://effectivehealthcare.ahrq.gov/products/prehospital-airway-management/research)

Examined the comparative benefits and harms across three airway management approaches (bag valve mask [BVM], supraglottic airway [SGA], and endotracheal intubation [ETI]) by emergency medical services in the prehospital setting. The most common findings, across emergency types and age groups, were of no differences in primary outcomes when prehospital airway management approaches were compared. Most of the included studies were observational and due to the dynamic nature of the prehospital environment the results are susceptible to indication and survival biases as well as confounding. The current evidence does not favour more invasive airway approaches but high-quality RCTS are needed.

Systematic search: Yes

June 2021

**Health Foundation**

[**Switched on: How do we get the best out of automation and AI in health care?**](https://www.health.org.uk/publications/reports/switched-on)

Explores the opportunities for automation and AI in health care and the challenges of deploying them in practice. Informed by YouGov online surveys of more than 4,000 UK adults and more than 1,000 NHS staff. The report finds that while automation and AI hold huge potential for improving care and productivity, in developing and deploying them we must be careful not to squeeze out the human dimension of health care. The health and care workforce require support to adapt to and shape technological change.

Systematic search: No

June 2021

**Canadian Agency for drugs and Technologies in Health (CADTH)**

[**Visual Examination Frequency for People Taking Ethambutol for Tuberculosis**](https://www.cadth.ca/visual-examination-frequency-people-taking-ethambutol-tuberculosis)

One guideline includes recommendations on the frequency of visual examinations for people with active tuberculosis who take ethambutol as part of their treatment. It recommends testing for visual acuity and colour vision before starting treatment and at every health care visit throughout the course of treatment with ethambutol (recommendations based on clinical experience).

Systematic search: Limited

May 2021

**McGill University Health Centre (Canada)**

Nil

**Health Information & Quality Authority (Ireland) – Health Technology Assessments**

Nil

**Campbell Collaboration**

Nil

**Glasgow Centre for Population Health**

Nil

**NICE FORWARD PLANNING – Publications due July 2021**

**Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency**

Single Technology Appraisal

**Subarachnoid haemorrhage due to ruptured aneurysms**

Clinical Guideline

**Type 1 diabetes in adults: diagnosis and management (update)**

Clinical Guideline

**Risdiplam for treating spinal muscular atrophy in children and adults**

Single Technology Appraisal

**Clostridioides difficile+B36 infection: antimicrobial prescribing**

Antimicrobial prescribing guideline